跳转至内容
Merck
CN

D1900000

地高辛

European Pharmacopoeia (EP) Reference Standard

别名:

异羟基洋地黄毒苷

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C41H64O14
化学文摘社编号:
20830-75-5
分子量:
780.94
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329798713
MDL number:
MFCD00003674
Beilstein/REAXYS Number:
77011

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

地高辛, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1

InChI key

LTMHDMANZUZIPE-PUGKRICDSA-N

SMILES string

C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]3[C@@H](O)C[C@@H](O[C@@H]3C)O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4

grade

pharmaceutical primary standard

API family

digoxin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... ATP1A1(476), ATP1A2(477), ATP1A3(478), ATP1A4(480), ATP1B1(481), ATP1B2(482), ATP1B3(483), FXYD2(486)

正在寻找类似产品? 访问 产品对比指南

相关类别

Application

地高辛EP 参考标准品设计用于欧洲药典规定的实验室测试。

Biochem/physiol Actions

一种强心苷，P-糖蛋白 (Pgp) 的底物。
一种强心苷，P-糖蛋白的底物，上调 Pgp 表达和下调 SXR（固醇类异生物受体）。

General description

本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。 如需进一步信息和支持，请访问现行药典网站。

Other Notes

可能适用相应的销售限制。

Packaging

本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 2 Oral - Acute Tox. 3 Inhalation - STOT RE 2

存储类别

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

法规信息

危险化学品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Chang Gong et al.
Cancer research, 74(16), 4341-4352 (2014-07-02)
Phyllodes tumors of breast, even histologically diagnosed as benign, can recur locally and have metastatic potential. Histologic markers only have limited value in predicting the clinical behavior of phyllodes tumors. It remains unknown what drives the malignant progression of phyllodes
Robert C Bourge et al.
The American journal of medicine, 126(8), 701-708 (2013-03-16)
Heart failure is a leading cause of hospital admission and readmission in older adults. The new United States healthcare reform law has created provisions for financial penalties for hospitals with higher than expected 30-day all-cause readmission rates for hospitalized Medicare
Ali Ahmed et al.
The American journal of medicine, 127(1), 61-70 (2013-11-22)
Heart failure is the leading cause for hospital readmission, the reduction of which is a priority under the Affordable Care Act. Digoxin reduces 30-day all-cause hospital admission in chronic systolic heart failure. Whether digoxin is effective in reducing readmission after
Georg Petschenka et al.
Proceedings. Biological sciences, 280(1759), 20123089-20123089 (2013-03-22)
Because cardenolides specifically inhibit the Na(+)K(+)-ATPase, insects feeding on cardenolide-containing plants need to circumvent this toxic effect. Some insects such as the monarch butterfly rely on target site insensitivity, yet other cardenolide-adapted lepidopterans such as the oleander hawk-moth, Daphnis nerii
Sibylle Neuhoff et al.
Journal of pharmaceutical sciences, 102(9), 3145-3160 (2013-05-25)
A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug-drug interactions between digoxin and P-gp inhibitors (e.g. verapamil and its metabolite norverapamil) or P-gp inducers (e.g. rifampicin) is a predictive pharmacokinetic model for digoxin itself. Thus, relevant in
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持